Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l

Item

http://www.wikidata.org/entity/Q38827600

Q38827600

about

Recent advances and novel treatment paradigms in acute lymphocytic leukemia Burkitt lymphoma in adolescents and young adults: management challenges.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.Immunotherapy approaches to treat adult acute lymphoblastic leukemia.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.The development of targeted new agents to improve the outcome for children with leukemia.Anti-CD20 monoclonal antibodies in multiple sclerosis.Novel therapy for childhood acute lymphoblastic leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 update Control of NK Cell Activation by Immune Checkpoint Molecules.The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).[Treatment of indolent cutaneous B‑cell lymphoma].Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.Tumor immunotherapy: New aspects of natural killer cells.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q28078076-FABAC4E6-96DD-4D70-8788-758A0FBD2222 Q30238965-E063400B-FAD7-4922-BC07-C012D2CCA011 Q30252776-7DBBBD08-886C-412B-8534-56001EE08698 Q33829283-D7F0FFE3-D278-445D-8D4F-5145C691F57D Q38640263-FB634489-3F81-4018-B5BC-CE0D9528D232 Q38666159-5FE840CA-26A9-45BE-AACF-D08C2DF9AF38 Q38740314-007CB715-21A8-4DF1-A51B-B7992E47AE9C Q38787405-64020EC0-CB08-4443-8AC4-5D745354D3E7 Q38803361-EE98981A-C631-4741-859A-992C7CFA6662 Q38964974-5CDABC28-B7F2-4775-8DD9-0C80736F234F Q38975695-76EDC059-7A8B-4C5E-9FC1-7E9B91C70A1C Q39368957-BDF372E0-F7B5-4BD4-A28D-979742A5CC45 Q39406969-21830C59-8975-40F4-912F-E11C3635C2C3 Q47128718-E37A1D0F-3ABA-4741-88F0-CE9C889B54A4 Q47809709-DB7F657A-3B24-442D-901A-9A226243BE65 Q48192887-D11EFB03-3B94-44AA-B373-AA7FCE3D9A62 Q48263835-55B801C5-7E1D-4F7B-94C1-B91E45AD3406 Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6 Q49561302-E941B247-ACBA-4D28-A3BA-61FFA17FFA9E Q50122599-C83A8303-2537-4D7B-A25C-62ABB8DFBF97 Q53130617-AF6225BA-9031-4822-98BA-C70994ADC098 Q54205796-2F0EF478-9200-4D2E-84AA-E9E07C9D3B73 Q55107050-78B902EC-CEB3-47C4-8C81-D8E1E92C53B7 Q55283747-63FCD492-7C92-4A18-9EFB-304668038E9C

P2860

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l

Item

http://www.wikidata.org/entity/Q38827600

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l

@en

type

Item

label

Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l

@en

prefLabel

Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l

@en

P1476

Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l

@en

P2093

Anthony Sabulski

http://www.w3.org/2001/XMLSchema#string

Aradhana Awasthi

http://www.w3.org/2001/XMLSchema#string

Carmella Van de Ven

http://www.w3.org/2001/XMLSchema#string

Christian Klein

http://www.w3.org/2001/XMLSchema#string

Humayun Islam

http://www.w3.org/2001/XMLSchema#string

Janet Ayello

http://www.w3.org/2001/XMLSchema#string

Matthew J Barth

http://www.w3.org/2001/XMLSchema#string

Mitchell S Cairo

http://www.w3.org/2001/XMLSchema#string

Mona Elmacken

http://www.w3.org/2001/XMLSchema#string

Myron S Czuczman

http://www.w3.org/2001/XMLSchema#string

P2860

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

P304

763-775

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13764

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26471982

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma

cytotoxicity

antibody

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l

about

P2860

P2860

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921